WASHINGTON, DC
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)ACCELERATE BRAIN CANCER CURE INC, founded in 2001, is a community nonprofit that reported $1.2M in total revenue in fiscal year 2019. Revenue fell 39% from the prior year — a significant decline worth monitoring. Expenses of $4.0M exceeded revenue, resulting in a 242% operating deficit.
TO ACCELERATE PROGRESS IN WHAT HAS BEEN AN UNDERSERVED FIELD OF RESEARCH; THE ORGANIZATION AIMS TO RAISE AWARENESS ABOUT BRAIN CANCER AND HELP MOBILIZE CRITICAL SCIENTIFIC RESEARCH THROUGH RESEARCH GRANTS.
ACCELERATE BRAIN CANCER CURE, INC. (ABC2) BELIEVES A FOCUSED AND AGGRESSIVE ENTREPRENEURIAL MODEL WILL INCREASE THE NUMBER OF THERAPIES DISCOVERED AND ENABLE THOSE THERAPIES TO BE AVAILABLE TO...
ACCELERATE BRAIN CANCER CURE, INC. (ABC2) BELIEVES A FOCUSED AND AGGRESSIVE ENTREPRENEURIAL MODEL WILL INCREASE THE NUMBER OF THERAPIES DISCOVERED AND ENABLE THOSE THERAPIES TO BE AVAILABLE TO DOCTORS AND PATIENTS MORE QUICKLY. ABC2 PROVIDES RESEARCHERS WITH THE PIVOTAL SUPPORT THEY NEED TO MAKE CRITICAL BREAKTHROUGHS. IT FUNDS TRANSLATIONAL RESEARCH AIMED AT FINDING THE FASTEST POSSIBLE ROUTE TO A CURE. ABC2 SUPPORTS A RANGE OF MEDICAL RESEARCH ORGANIZATIONS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2019 | 2018 | Change | |
|---|---|---|---|
| Revenue | $1,166,711 | $1,915,355 | -0.4% |
| Expenses | $3,986,099 | $1,584,284 | +1.5% |
| Net Income | $-2,819,388 | $331,071 | -9.5% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| STEVE CASE | CHAIRMAN & CO-FOUNDER | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| STACEY CASE | CO-FOUNDER | 1.00 |
Director
|
$0 | $0 | $0 |
| NANCY PFUND | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| DAVID COLE | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| JEAN CASE | CO-FOUNDER | 1.00 |
Director
|
$0 | $0 | $0 |
| DOUG HOLLADAY | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| JONATHAN WEINBERG | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| GARY WIMMER | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| MAX WALLACE | PRESIDENT AND CEO | 40.00 |
Officer
|
$536,539 | $16,338 | $552,877 |
| DAVID SANDAK | VP/SECRETARY/TREASURER | 40.00 |
Officer
|
$318,748 | $12,864 | $331,612 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2019 | $1,166,711 | $3,986,099 | No data | $-2,819,388 |
| 2018 | $1,915,355 | $1,584,284 | $3,099,618 | $331,071 |
Compare ACCELERATE BRAIN CANCER CURE INC with other nonprofits in District of Columbia and across the country.